Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study

IntroductionEffective treatment during the metastatic hormone-sensitive prostate cancer (mHSPC) stage is crucial for delaying disease progression. Due to the lack of a head-to-head comparison of darolutamide (DARO) and abiraterone acetate plus prednisone (AAP) doublet regimen, this study aims to com...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Ting Hu, Fang Zhou, Yang Zheng, Bohan Luo, Yongliang Zhang, Chengpeng Gu, Guopeng Wang, Jinze Zhang, Jingzhi Tian, Yu Nie, Yunlin Feng, Shangqing Ren, Wenjia Di, Dong Wang
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2025-06-01
Rangatū:	Frontiers in Pharmacology
Ngā marau:	metastatic hormone-sensitive prostate cancer darolutamide abiraterone acetate androgen deprivation therapy efficacy safety
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1608339/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!